Efficacy of high dosage of betahistine in patients with unilateral peripheral vestibulopathy

Efficacy of high dosage of betahistine in patients with unilateral peripheral vestibulopathy - Efficacy of high dosage of betahistine in patients with unilateral peripheral vestibulopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017711

Enrollment

225

Registered

2015-07-01

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unilateral peripheral vestibulopathy

Interventions

Oral administration of high dosage of betahistine mesilate (72mg/day) for 4 weeks Oral administration of ordinary dosage of betahistine mesilate (36mg/day) for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult (20-80 y/o) patients with unilateral peripheral vestibulopathy except Meniere's disease and benign paroxysmal positional vertigo, who complains of persistent dizziness for 3 months.

Exclusion criteria

Exclusion criteria: 1) Patients with peptic ulcer. 2) Patients with bronchial asthma. 3) Patients with pheochromocytoma. 4) Pregnant and breast-feeding female patients 5) Patients who suffered from repetitive vertigo attacks 6) Patients who was excluded by investigators.

Design outcomes

Primary

Measure	Time frame
Dizziness Handicap Inventory score	—

Secondary

Measure	Time frame
Vestibular function	—

Countries

Japan

Contacts

Public ContactNoriaki Takeda

University of Tokushima School of Medicine Department of Otolaryngology

takeda@tokushima-u.ac.jp088-633-7169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026